These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 20385333)

  • 1. Immunopathogenesis of thyroid eye disease: emerging paradigms.
    Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS
    Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
    Wang R; Song D; Zhong Y; Li H
    BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
    Smith TJ; Hegedüs L; Douglas RS
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current understanding of pathogenesis of Graves ophthalmopathy].
    Ando T; Eguchi K
    Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.
    Douglas RS; Naik V; Hwang CJ; Afifiyan NF; Gianoukakis AG; Sand D; Kamat S; Smith TJ
    J Immunol; 2008 Oct; 181(8):5768-74. PubMed ID: 18832736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
    Wiersinga WM
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
    Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
    J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Aspects of Graves' Ophthalmopathy.
    Łacheta D; Miśkiewicz P; Głuszko A; Nowicka G; Struga M; Kantor I; Poślednik KB; Mirza S; Szczepański MJ
    Biomed Res Int; 2019; 2019():7453260. PubMed ID: 31781640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
    Khong JJ; McNab AA; Ebeling PR; Craig JE; Selva D
    Br J Ophthalmol; 2016 Jan; 100(1):142-50. PubMed ID: 26567024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy.
    Naik V; Khadavi N; Naik MN; Hwang C; Goldberg RA; Tsirbas A; Smith TJ; Douglas RS
    Thyroid; 2008 Sep; 18(9):967-71. PubMed ID: 18713027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.
    Iyer S; Bahn R
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):281-9. PubMed ID: 22632365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy.
    Weightman DR; Perros P; Sherif IH; Kendall-Taylor P
    Autoimmunity; 1993; 16(4):251-7. PubMed ID: 7517705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
    Dik WA; Virakul S; van Steensel L
    Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
    Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
    Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.